HK1158057A1 - Pharmaceutical composition for treating hypertension and metabolic syndrome and use thereof - Google Patents

Pharmaceutical composition for treating hypertension and metabolic syndrome and use thereof

Info

Publication number
HK1158057A1
HK1158057A1 HK11112324.9A HK11112324A HK1158057A1 HK 1158057 A1 HK1158057 A1 HK 1158057A1 HK 11112324 A HK11112324 A HK 11112324A HK 1158057 A1 HK1158057 A1 HK 1158057A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical composition
metabolic syndrome
treating hypertension
hypertension
treating
Prior art date
Application number
HK11112324.9A
Other languages
English (en)
Chinese (zh)
Inventor
趙志全
Original Assignee
魯南制藥集團股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 魯南制藥集團股份有限公司 filed Critical 魯南制藥集團股份有限公司
Publication of HK1158057A1 publication Critical patent/HK1158057A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK11112324.9A 2008-07-24 2011-11-15 Pharmaceutical composition for treating hypertension and metabolic syndrome and use thereof HK1158057A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2008101337534A CN101632672B (zh) 2008-07-24 2008-07-24 一种用于治疗高血压的复方药物组合物
PCT/CN2009/000824 WO2010009619A1 (zh) 2008-07-24 2009-07-23 用于治疗高血压和代谢综合症的药物组合物及其应用

Publications (1)

Publication Number Publication Date
HK1158057A1 true HK1158057A1 (en) 2012-07-13

Family

ID=41570004

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11112324.9A HK1158057A1 (en) 2008-07-24 2011-11-15 Pharmaceutical composition for treating hypertension and metabolic syndrome and use thereof

Country Status (7)

Country Link
US (1) US8722697B2 (ja)
EP (1) EP2329820B1 (ja)
JP (1) JP5504263B2 (ja)
KR (1) KR101303841B1 (ja)
CN (1) CN101632672B (ja)
HK (1) HK1158057A1 (ja)
WO (1) WO2010009619A1 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2977048A4 (en) * 2013-03-12 2017-04-26 LG Life Sciences Ltd. Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor
KR101910901B1 (ko) * 2013-11-29 2018-10-24 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제
KR101663550B1 (ko) * 2014-06-11 2016-10-07 조선대학교산학협력단 주석산을 유효성분으로 포함하는 고혈압 예방 또는 치료용 약학조성물 및 건강기능식품
KR101920996B1 (ko) * 2017-04-26 2018-11-22 알보젠코리아 주식회사 HMG-CoA 환원효소 저해제 및 칼슘채널 차단제를 포함하는 복합제제

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0027410D0 (en) * 2000-11-09 2000-12-27 Pfizer Ltd Mutual prodrug of amlodipine and atorvastatin
BRPI0410555A (pt) * 2003-06-06 2006-06-20 Takeda Pharmaceutical preparação sólida
CN100389830C (zh) * 2005-05-08 2008-05-28 广州市施柏医药科技有限公司 一种治疗高血压的药物组合物
CN1762361A (zh) 2005-09-28 2006-04-26 扬子江药业集团有限公司 一种含有苯磺酸氨氯地平和瑞舒伐他汀钙的药物组合物及其制备方法
CN101360743A (zh) * 2006-01-30 2009-02-04 Irm责任有限公司 作为ppar调节剂的多环的1,2,3,4-四氢-异喹啉衍生物和包含它们的组合物
CN101095680A (zh) 2006-06-30 2008-01-02 信谊药厂 含有瑞舒伐他汀钙和氨氯地平的制剂及其制备方法
MXPA06010973A (es) * 2006-09-25 2009-02-18 World Trade Imp Export Wtie Ag Composicion farmaceutica para el tratamiento del sobrepeso y la obesidad que se acompañan la dislipidemia.
CN101167724B (zh) * 2006-10-25 2012-08-22 北京华安佛医药研究中心有限公司 含有氨氯地平的药物组合物在制备治疗下尿路疾病药物中的用途
CN101229372B (zh) * 2007-01-26 2010-09-01 鲁南制药集团股份有限公司 一种治疗高血压的药物组合物
JP2010536880A (ja) * 2007-08-22 2010-12-02 ギリード・コロラド・インコーポレーテッド 糖尿病の合併症のための療法

Also Published As

Publication number Publication date
JP5504263B2 (ja) 2014-05-28
EP2329820B1 (en) 2015-04-08
CN101632672A (zh) 2010-01-27
KR20110033940A (ko) 2011-04-01
EP2329820A1 (en) 2011-06-08
JP2011528670A (ja) 2011-11-24
EP2329820A4 (en) 2011-11-02
US8722697B2 (en) 2014-05-13
US20110130416A1 (en) 2011-06-02
CN101632672B (zh) 2011-01-12
WO2010009619A1 (zh) 2010-01-28
KR101303841B1 (ko) 2013-09-05

Similar Documents

Publication Publication Date Title
IL275854A (en) Pharmaceutical composition and its administration
IL271132A (en) New preparation and dosage
IL206288A0 (en) Novel dosage and formulation
ZA200904972B (en) Novel composition for treating metabolic syndrome
EP2322175A4 (en) PHARMACEUTICAL COMPOSITION FOR TREATING HYPERTENSION AND METABOLIC SYNDROME AND USE THEREOF
EP2291157A4 (en) COMPOSITIONS AND METHODS FOR TRANSDERING DELIVERY OF PHARMACEUTICAL COMPOUNDS
IL228817A0 (en) Pharmaceutical compounds
EP2184986A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHRONIC PAIN AND PAIN RELATING TO NEUROPATHY
IL210843A0 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
IL212707A0 (en) Compounds, pharmaceutical composition and methods for use in treating metabolic disorders
EP2216038A4 (en) PHARMACEUTICAL COMPOSITIONS FOR TREATING DEPRESSION AND ANXIETY
IL208387A0 (en) Pharmaceutical composition
GB2469220B (en) Pharmaceutical composition for treating diabetes and preparation method thereof
EP2609922A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CHRONIC ILL DISEASES AND USE THEREOF
HK1158057A1 (en) Pharmaceutical composition for treating hypertension and metabolic syndrome and use thereof
EP2431041A4 (en) PHARMACEUTICAL COMPOSITION FOR TREATING CARDIOVASCULAR DISORDER AND USE THEREOF
HK1162858A1 (en) Topical compositions containing cis-6-nonenol and its derivatives and methods for treating skin -6-
ZA201006224B (en) Pharmaceutical composition
IL218726A0 (en) Methods and pharmaceutical compositions for treating down syndrome
GB2464200B (en) Pharmaceutical composition
AP3008A (en) Pupicidal and larvicidal composition
HK1155062A1 (en) Pharmaceutical composition and combined agent
GB2461611B (en) Composition and use thereof
EP2344528A4 (en) DRUGS AND FIBROSIS, ITS COMPOSITION AND USES
GB0714500D0 (en) composition and treatment

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210727